Literature DB >> 31338669

Iatrogenic hypoglycemia-related hospital admissions identified through databases: economic burden and causes.

Tiphaine Richard1, Romane Issa2, Emmanuel Andres3, Bénédicte Gourieux1, Nathalie Jeandidier4, Bruno Michel5,6,7.   

Abstract

Background Hypoglycemia is an acute and frequent complication of diabetes. Objectives To assess the number of hospital admissions due to iatrogenic hypoglycemia in Alsace (France) over a year, to estimate the associated economic burden and to identify causes. Method A retrospective analysis was performed using data extracted from hospital databases. Costs were calculated from French official tariffs. Setting 31 public and private hospitals. A review of the medical records of patients with iatrogenic hypoglycemia-related hospital admissions was performed at the University Hospital of Strasbourg. Main outcome measures Hypoglycemia-related hospital admissions: number, costs and causes. Results Out of 42,381 hospitalizations, 147 iatrogenic hypoglycemia-related hospital admissions (0.4%) were identified; 41 patients with type 1 diabetes mellitus and 106 with type 2. The total cost associated to the 147 events was € 407,441. The median cost per patient was € 1,224.6 [563.0-2,505.7 (interquartile range)] for type 1 diabetes mellitus and € 3,670.9 [2,505.7-3,670.9] for type 2. Forty-six patients over the 147 were coming from the University Hospital of Strasbourg. In this hospital, the most common origin of the hypoglycemia was missed meals (n = 7), the second was a mismatch between antidiabetic medicines and carbohydrate intake (n = 6), the third was an incorrect use of antidiabetic medicines (n = 5). Conclusions 147 hospitalizations due to iatrogenic hypoglycemia were identified with an estimated global cost of € 407,441. Optimizing therapy with low-risk hypoglycemic medicines, improving access to continuous glucose monitoring systems and offering adequate education, could help address the causes of hypoglycemia.

Entities:  

Keywords:  France; Hospital admission; Iatrogenic hypoglycemia; Inappropriate prescription; Therapeutic education

Mesh:

Substances:

Year:  2019        PMID: 31338669     DOI: 10.1007/s11096-019-00877-5

Source DB:  PubMed          Journal:  Int J Clin Pharm


  21 in total

1.  Severe hypoglycaemia the "tip of the iceberg": an underestimated risk in both type 1 and type 2 diabetic patients.

Authors:  S Halimi
Journal:  Diabetes Metab       Date:  2015-03-29       Impact factor: 6.041

2.  Direct medical costs of complications of diabetes in the United States: estimates for event-year and annual state costs (USD 2012).

Authors:  Alex Ward; Piedad Alvarez; Lien Vo; Silas Martin
Journal:  J Med Econ       Date:  2014-01-28       Impact factor: 2.448

3.  Direct and indirect health economic impact of hypoglycaemia in a global population of patients with insulin-treated diabetes.

Authors:  Ronnie Aronson; Gagik Galstyan; Margalit Goldfracht; Saud Al Sifri; Lisa Elliott; Kamlesh Khunti
Journal:  Diabetes Res Clin Pract       Date:  2018-01-31       Impact factor: 5.602

4.  Direct medical costs of severe hypoglycaemic events in patients with type 2 diabetes in England: A retrospective database study.

Authors:  Tim Holbrook; Yuexin Tang; Romita Das; R Ravi Shankar; Kaan Tunceli; Jean Williams; Larry Radican; Sarah E Holden; Chris Ll Morgan; James Piercy; Craig J Currie
Journal:  Int J Clin Pract       Date:  2017-05-23       Impact factor: 2.503

5.  Frequency and predictors of confirmed hypoglycaemia in type 1 and insulin-treated type 2 diabetes mellitus patients in a real-life setting: results from the DIALOG study.

Authors:  B Cariou; P Fontaine; E Eschwege; M Lièvre; D Gouet; D Huet; S Madani; S Lavigne; B Charbonnel
Journal:  Diabetes Metab       Date:  2014-11-24       Impact factor: 6.041

6.  Costs of managing severe hypoglycaemia in three European countries.

Authors:  Mette Hammer; Morten Lammert; Susana Monereo Mejías; Werner Kern; Brian M Frier
Journal:  J Med Econ       Date:  2009       Impact factor: 2.448

7.  Effects of intensive glucose lowering in type 2 diabetes.

Authors:  Hertzel C Gerstein; Michael E Miller; Robert P Byington; David C Goff; J Thomas Bigger; John B Buse; William C Cushman; Saul Genuth; Faramarz Ismail-Beigi; Richard H Grimm; Jeffrey L Probstfield; Denise G Simons-Morton; William T Friedewald
Journal:  N Engl J Med       Date:  2008-06-06       Impact factor: 91.245

8.  Anticoagulant-related hospital admissions: serious adverse reactions identified through hospital databases.

Authors:  Charles Heng; Marie Christine Rybarczyk-Vigouret; Bruno Michel
Journal:  Pharmacoepidemiol Drug Saf       Date:  2014-07-31       Impact factor: 2.890

9.  Long-term effect of an education program (HyPOS) on the incidence of severe hypoglycemia in patients with type 1 diabetes.

Authors:  Norbert Hermanns; Bernd Kulzer; Michael Krichbaum; Thomas Kubiak; Thomas Haak
Journal:  Diabetes Care       Date:  2010-03       Impact factor: 19.112

10.  Clinical and Cost Implications of Insulin Degludec in Patients with Type 1 Diabetes and Problematic Hypoglycemia: A Quality Improvement Project.

Authors:  Muhammad Ali Karamat; Shujah Dar; Srikanth Bellary; Abd A Tahrani
Journal:  Diabetes Ther       Date:  2018-03-16       Impact factor: 2.945

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.